BioLingus (Cayman) Limited (SUBL)

BioLingus (Cayman) Limited will go public soon, but the exact IPO date is still unknown.
IPO Price
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 222.25M
Revenue (ttm) n/a
Net Income (ttm) -584,786
Shares Out 11.11M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SUBL

BioLingus in an exempted company with limited liability incorporated under the laws of the Cayman Islands, which is structured as a holding company whose main business operations are conducted through our subsidiaries in Switzerland and to a lesser extent, HK SAR, the People’s Republic of China and Australia. We are a biotechnology company spearheading the development of oral (specifically, sublingual) delivery of peptides and proteins. The main peptide used to improve the technology was exenatide, which was the first commercial glucagon-like p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 15
Stock Exchange NASDAQ
Ticker Symbol SUBL
Full Company Profile

Financial Performance

Financial Statements


Biotech BioLingus files for IPO

BioLingus, a Swiss biotech company incorporated in the Cayman Islands, filed for an IPO on Friday. The company intends to trade on the Nasdaq Capital Market under the ticker symbol “SUBL.

8 months ago - Market Watch

BioLingus IPO Registration Document (F-1)

BioLingus has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC